Aquestive Therapeutics (AQST) Revenue (2017 - 2025)
Historic Revenue for Aquestive Therapeutics (AQST) over the last 9 years, with Q3 2025 value amounting to $12.8 million.
- Aquestive Therapeutics' Revenue fell 542.76% to $12.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$13.2 million, marking a year-over-year decrease of 12233.62%. This contributed to the annual value of $1.0 million for FY2024, which is 9800.72% down from last year.
- Aquestive Therapeutics' Revenue amounted to $12.8 million in Q3 2025, which was down 542.76% from $10.0 million recorded in Q2 2025.
- Aquestive Therapeutics' Revenue's 5-year high stood at $20.1 million during Q2 2024, with a 5-year trough of -$44.7 million in Q4 2024.
- Its 5-year average for Revenue is $8.4 million, with a median of $11.5 million in 2022.
- As far as peak fluctuations go, Aquestive Therapeutics' Revenue soared by 30000.0% in 2021, and later crashed by 43837.65% in 2024.
- Quarter analysis of 5 years shows Aquestive Therapeutics' Revenue stood at $11.1 million in 2021, then fell by 3.57% to $10.7 million in 2022, then increased by 23.63% to $13.2 million in 2023, then plummeted by 438.38% to -$44.7 million in 2024, then soared by 128.66% to $12.8 million in 2025.
- Its last three reported values are $12.8 million in Q3 2025, $10.0 million for Q2 2025, and $8.7 million during Q1 2025.